海特生物(300683) - 2020 Q1 - 季度财报

Financial Performance - Total operating revenue for Q1 2020 was ¥64,692,430.52, a decrease of 58.61% compared to ¥156,308,732.68 in the same period last year[7] - Net profit attributable to shareholders was ¥4,250,575.75, down 85.76% from ¥29,854,699.68 year-on-year[7] - The net profit after deducting non-recurring gains and losses was -¥912,044.87, a decline of 103.47% compared to ¥26,295,585.08 in the previous year[7] - Basic and diluted earnings per share were both ¥0.04, down 86.21% from ¥0.29 in the previous year[7] - The weighted average return on net assets was 0.24%, down 1.50% from 1.74% year-on-year[7] - The company reported total revenue of ¥64,692,430.52, a decrease of 58.61% compared to the same period last year, primarily due to the impact of the pandemic and industry policy adjustments[20] - Net profit attributable to shareholders was ¥4,250,575.75, down 85.76% year-on-year, influenced by increased R&D expenses amid challenging market conditions[20] - The total operating revenue for Q1 2020 was CNY 35,661,736.10, a decrease from CNY 111,563,797.17 in the previous period[46] - The net profit for Q1 2020 was CNY 4,052,881.96, compared to CNY 29,274,813.57 in the same period last year, representing a decline of approximately 86.2%[43] - The operating profit for Q1 2020 was CNY 4,003,105.48, down from CNY 36,015,025.81 in the previous year, indicating a significant decrease of about 88.9%[43] - The total comprehensive income for Q1 2020 was CNY 4,052,881.96, down from CNY 29,274,813.57 in the previous year, indicating a decline of approximately 86.2%[44] Cash Flow and Investments - Net cash flow from operating activities was ¥5,040,127.69, a decrease of 72.36% from ¥18,232,746.92 in the same period last year[7] - Cash received from sales of goods and services decreased by 47.30% to ¥166,143,664.39, reflecting reduced sales and cash collection due to the pandemic[19] - The company’s cash flow from operating activities decreased by 66.13% to ¥92,070,227.12, attributed to business slowdown from the pandemic[19] - The cash inflow from operating activities was CNY 92,925,757.90, down from CNY 170,807,394.71 in the previous period[50] - The net cash flow from investing activities was -115,974,367.24 CNY, worsening from -27,553,949.36 CNY in the previous period[51] - Cash inflow from investment activities totaled 172,065,458.06 CNY, significantly higher than 4,874,236.90 CNY in the previous period[51] - The company reported a significant increase in cash inflow from investment recovery, totaling 105,000,000.00 CNY[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,172,082,531.55, an increase of 0.12% from ¥2,169,508,822.12 at the end of the previous year[7] - Net assets attributable to shareholders at the end of the reporting period were ¥1,755,902,038.39, up 0.21% from ¥1,752,293,190.99 at the end of the previous year[7] - Total current assets as of March 31, 2020, are 1,459,700,825.59[33] - Total liabilities were CNY 309,460,746.56, compared to CNY 302,863,570.22 in the previous period[39] - Owner's equity reached CNY 1,726,901,021.15, slightly increasing from CNY 1,723,307,270.63 in the previous period[39] - Long-term liabilities were recorded at CNY 7,539,362.48, suggesting manageable debt levels[61] - The total liabilities and owner's equity combined reached CNY 2,026,170,840.85, reflecting a balanced financial structure[61] Research and Development - The company is advancing the clinical trial for its CPT drug, which targets multiple myeloma, with plans for new drug registration and market launch[21] - Research and development expenses for Q1 2020 were CNY 10,613,763.54, slightly lower than CNY 10,996,448.47 in the previous period[42] Government Support and Shareholder Information - The company received government subsidies amounting to ¥881,091.81 during the reporting period[8] - The total number of ordinary shareholders at the end of the reporting period was 17,731[11] Investment Projects - The company increased its long-term equity investments to ¥5,000,000.00, marking a 100% increase due to new external investments[18] - The company’s intangible assets rose by 42.46% to ¥90,877,995.45, primarily due to the acquisition of land[18] - Investment payments surged by 3905.81% to ¥275,600,000.00, driven by new long-term investments and increased financial products purchases[19] - The total amount of committed investment projects is 79,747.59 million, with 42,979 million already invested[26] - The investment in the biological engineering drug comprehensive preparation base upgrade project is 22,000 million, with a progress rate of 21.03%[25] - The R&D center and laboratory construction project has a total investment of 38,030 million, with a completion rate of 141.24%[25] - The marketing service network upgrade project has an investment of 10,188 million, with a progress rate of 1.91%[25] Financial Reporting and Audit - The company has not undergone an audit for the first quarter report, which may affect investor confidence[63] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[62]